

Special Issue

The Role of Cancer Stem Cells in Cancer Targeted Therapy

Message from the Guest Editor

With advancement of our understanding about Cancer Stem Cells, their eventual value as targets for cancer therapy has become an important area in molecular oncology and cancer therapeutics. This special issue aims to provide the reader with an appropriate level of understanding about important biological and genetic features of cancer stem cells along with the translational strategies that usurp such features to target these cells. Within this issue you will find drug and gene therapy based strategies that target cancer stem cells. Special articles will also focus on certain tumor types and the level of knowledge about cancer stem cells. Research areas may include (but are not limited to) the following:

- Cancer stem cell (CSC) biology
- Molecular genetics of CSCs
- Markers of CSCs
- Pro-oncogenic pathways involved in CSCs biology
- Therapeutic strategies targeting CSCs
- Drug therapies targeting CSCs
- Genetic therapies targeting cancer stem cells
- Oncolytic viruses targeting CSCs
- Immune based therapies targeting cancer stem cells
- Tumor specific attempts to target CSCs

Guest Editor

Dr. Faris Farassati

Medicine Department of Medicine-Molecular Medicine Laboratory, The University of Kansas Medical Center, Kansas City, MO, USA

Deadline for manuscript submissions

closed (10 October 2023)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/119601

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)